CN1209362C - 四唑基－苯基乙酰胺的葡糖激酶激活剂 - Google Patents

四唑基－苯基乙酰胺的葡糖激酶激活剂 Download PDF

Info

Publication number
CN1209362C
CN1209362C CNB018163475A CN01816347A CN1209362C CN 1209362 C CN1209362 C CN 1209362C CN B018163475 A CNB018163475 A CN B018163475A CN 01816347 A CN01816347 A CN 01816347A CN 1209362 C CN1209362 C CN 1209362C
Authority
CN
China
Prior art keywords
methyl
phenyl
reaction mixture
mmol
cyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018163475A
Other languages
English (en)
Chinese (zh)
Other versions
CN1466584A (zh
Inventor
阿奇犬塔罗·西杜瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1466584A publication Critical patent/CN1466584A/zh
Application granted granted Critical
Publication of CN1209362C publication Critical patent/CN1209362C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB018163475A 2000-08-15 2001-08-09 四唑基－苯基乙酰胺的葡糖激酶激活剂 Expired - Fee Related CN1209362C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22549400P 2000-08-15 2000-08-15
US60/225,494 2000-08-15

Publications (2)

Publication Number Publication Date
CN1466584A CN1466584A (zh) 2004-01-07
CN1209362C true CN1209362C (zh) 2005-07-06

Family

ID=22845106

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018163475A Expired - Fee Related CN1209362C (zh) 2000-08-15 2001-08-09 四唑基－苯基乙酰胺的葡糖激酶激活剂

Country Status (20)

Country Link
US (3) US6369232B1 (enExample)
EP (1) EP1311504B1 (enExample)
JP (1) JP3961948B2 (enExample)
KR (1) KR100518061B1 (enExample)
CN (1) CN1209362C (enExample)
AR (1) AR031718A1 (enExample)
AT (1) ATE297921T1 (enExample)
AU (2) AU8399801A (enExample)
BR (1) BR0113312A (enExample)
CA (1) CA2419416C (enExample)
DE (1) DE60111540T2 (enExample)
DK (1) DK1311504T3 (enExample)
ES (1) ES2243541T3 (enExample)
MX (1) MXPA03001275A (enExample)
PA (1) PA8525201A1 (enExample)
PE (1) PE20020386A1 (enExample)
PT (1) PT1311504E (enExample)
UY (1) UY26885A1 (enExample)
WO (1) WO2002014312A1 (enExample)
ZA (1) ZA200300904B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
EP1594863A1 (en) * 2003-02-11 2005-11-16 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
KR20070006816A (ko) 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
KR100830007B1 (ko) 2004-04-02 2008-05-15 노파르티스 아게 2형 당뇨병 치료에 유용한 글루코키나제 활성화제로서의술폰아미드-티아졸피리딘 유도체
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
CN101218237B (zh) * 2005-07-11 2012-03-28 田边三菱制药株式会社 肟衍生物及其制备方法
EP1921074A1 (en) 2005-08-31 2008-05-14 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
BRPI0618062A2 (pt) * 2005-11-03 2011-08-16 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
ES2381864T3 (es) * 2005-12-15 2012-06-01 Nihon Nohyaku Co., Ltd. Derivado de ftalamida, pesticida agrícola u hortícola y utilización del pesticida
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8314247B2 (en) * 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative
KR20090121376A (ko) 2007-03-07 2009-11-25 교린 세이야꾸 가부시키 가이샤 글루코키나아제 활성화 물질
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AU2008310519B2 (en) * 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
EP2236498A4 (en) * 2008-01-18 2012-02-22 Astellas Pharma Inc PHENYLACETAMIDE DERIVATIVE
CA2722733C (en) * 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5859052A (en) * 1993-01-14 1999-01-12 G. D. Searle & Co. Fatty acid analogs and prodrugs
US5461049A (en) * 1994-05-27 1995-10-24 Warner-Lambert Company Amide tetrazole ACAT inhibitors
US5468867A (en) * 1994-05-27 1995-11-21 Syntex (U.S.A.) Inc. Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid
PL334833A1 (en) * 1997-01-28 2000-03-27 Merck & Co Inc Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity
BR0009486B1 (pt) * 1999-03-29 2011-03-09 composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo.

Also Published As

Publication number Publication date
CA2419416C (en) 2009-10-13
UY26885A1 (es) 2002-02-28
WO2002014312A1 (en) 2002-02-21
US20020065275A1 (en) 2002-05-30
US20020035266A1 (en) 2002-03-21
KR100518061B1 (ko) 2005-09-28
AU8399801A (en) 2002-02-25
BR0113312A (pt) 2003-07-01
ES2243541T3 (es) 2005-12-01
EP1311504A1 (en) 2003-05-21
EP1311504B1 (en) 2005-06-15
CA2419416A1 (en) 2002-02-21
MXPA03001275A (es) 2003-06-30
US6388088B1 (en) 2002-05-14
US20020035267A1 (en) 2002-03-21
PE20020386A1 (es) 2002-05-13
ATE297921T1 (de) 2005-07-15
JP2004506632A (ja) 2004-03-04
ZA200300904B (en) 2004-04-30
DE60111540T2 (de) 2006-03-16
DE60111540D1 (de) 2005-07-21
JP3961948B2 (ja) 2007-08-22
PA8525201A1 (es) 2002-07-30
PT1311504E (pt) 2005-10-31
AU2001283998B2 (en) 2005-10-20
AR031718A1 (es) 2003-10-01
US6441180B1 (en) 2002-08-27
DK1311504T3 (da) 2005-10-17
KR20030022408A (ko) 2003-03-15
US6369232B1 (en) 2002-04-09
CN1466584A (zh) 2004-01-07

Similar Documents

Publication Publication Date Title
CN1209362C (zh) 四唑基－苯基乙酰胺的葡糖激酶激活剂
CN1226294C (zh) 稠合的杂芳族葡萄糖激酶活化剂
CN1184214C (zh) α－酰基和α－杂原子取代的苯乙酰胺葡糖激酶活化剂
CN1185219C (zh) 反式烯属葡糖激酶活化剂
CN1247574C (zh) 异吲哚啉－1－酮葡糖激酶激活剂
CN1151140C (zh) 葡糖激酶活化剂
CN1245394C (zh) 作为葡糖激酶激活剂的取代的苯乙酰胺及其用途
CN1185220C (zh) 对－胺基取代的苯基酰胺葡糖激酶激活剂
CN1066436C (zh) 新的环己烷和环己烯类衍生物
CN1131210C (zh) 杂环类酰胺化合物及其医药用途
CN1688574A (zh) 作为葡糖激酶(gk)激活剂的吲哚－3－甲酰胺
CN1649859A (zh) 取代的苯基乙酰胺类及其作为葡糖激酶激活剂的应用
CN1050018A (zh) 苯甲酰基胍、它们的制备方法、它们作为药剂的应用以及含有它们的药剂
CN1060652A (zh) 草酰胺类
CN1897936A (zh) 环状胍、含有这种化合物的组合物及其使用方法
CN1374082A (zh) 糖原磺酸化酶抑制剂的用途
AU2001283998A1 (en) Tetrazolyl-phenyl acetamide glucokinase activators
CN1056684A (zh) 异唑-4-羧酰胺及羟基亚烷基氰乙酰胺，含有这些化合物的药物及它们的应用
CN1638768A (zh) 调节ppar活性的噻唑和噁唑衍生物
CN1171785A (zh) 嘧啶衍生物
CN1290842C (zh) 用作高选择性环加氧酶－2抑制剂的二芳基1,2,4－三唑衍生物
CN1090020C (zh) 4,4－(二取代)环己－1－醇单体及相关的化合物
CN1292744C (zh) 抑制整联蛋白与其受体结合的羧酸衍生物
CN1993336A (zh) 取代的n－酰基－2－氨基噻唑
HK1063314B (en) Isoindolin-1-one glucokinase activators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050706

Termination date: 20120809